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Interferons (IFN) are aclass ofinducible proteins that have been definedby their
ability to protect cells from viral infections andare antigenically subclassified as IFN-a,
-(3, and -y (1) . IFN also possess many potent and diverse immunoregulatory activi-
ties (1) . Elevated levels ofIFN have been detected in theserumand plasma ofmany
patients with systemic lupus erythematosus (SLE) and other autoimmune diseases
(2-5), and also in patients with AIDS (6), a disorder now recognized to involve
many SLE-likeautoimmune phenomena (7). Notably, in SLE andin AIDS, serum
IFN levels correlate positively with disease activity (2, 8) . The IFN in these im-
munoregulatory disorders hasbeen postulated to be oneor more atypical subspecies
of IFN-a that becomes inactivated after dialysis at pH 2, unlike other well-
characterized IFN-a(3-6) . Some investigators have used the term autoimmune inter
feron to describe this activity (9) . Although it is an attractive possibility that struc-
tural differences in this IFN-a that cause acid labilitymay also constitute functional
determinants that mediate the autoimmune effects seen in these diseases, there is
no direct evidence for this assertion, and the true nature of acid lability is not known .
This study was conducted to examine the physicochemical properties of SLE-
associated IFN-a(SLE IFN-a) to identify additional physical differences fromknown
IFN and to eventually purify the molecule for further analysis. The results show
that SLE IFN-a is physicochemically indistinguishable from conventional IFN-a
and that acid lability is not an intrinsic property ofSLE IFN-a, but rather the result
of other factor(s) in SLE plasma .
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Materials and Methods
Patient Population.
￿
Sera and plasma were collected from individuals who fulfilled at least
four criteria for the diagnosis ofSLE as established by the American Rheumatism Associa-
tion (10) . Normal sera and plasma were obtained from volunteer donors at the NYU Medi-
cal Center Blood Donor Program .
IFNAssays andAcid-Labiliy Tests.
￿
Antiviral activity was determined in duplicate by pre-
viously described methods (11) . IFN titers are defined as the dilutions at which 50% of FS-4
fibroblasts are protected from the cytopathic effects of encephalomyocarditis virus 24 h after
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infection and are expressed as IU/ml based on human IFN-a standard G-023-091-527 (Na-
tional Institutes of Health, Bethesda, MD). Samples were tested for acid lability by dialysis
in 100 mM glycine-HCI (pH 2) for 24 h at 4°C, followed by dialysis in PBS (pH 7.4) for
another 24 h at 4°C (3). Control preparations were dialyzed in PBS throughout the 48 h.
StandardInterferons and NeutralizingAntibodies.
￿
NK-2 IFN-a is a natural preparation of differ-
ent IFN-a produced by human lymphoblastoid cells (Celltech Limited, Berkshire, UK).
Purified human rIFN-a2 and rIFN-Q,er1, were from Schering Corp. (Bloomfield, NJ) and
Cetus Corp. (Emeryville, CA), respectively. Human IFN-y was prepared according to the
method ofYip et al. (11). Polyclonal sheep anti-IFN-a antibodies were obtained from Inter-
feron Sciences, Inc. (New Brunswick, NJ). Polyclonal bovine anti-IFN-(3 antibodies were
provided by Dr. Jan ViRek (NYU School of Medicine, New York, NY). Polyclonal rabbit
anti-IFN-y antibodies were prepared by published methods (12). Antibody neutralization
assays, described elsewhere (3), were conducted using preimmune sheep, bovine, or rabbit
sera as negative controls. rIFN-a2 was radioiodinated with 1z'I using the Bolton-Hunter re-
agent (reference 13; New England Nuclear, Boston, MA).
Fast Protein Liquid Chromatography (FPLC).'
￿
All chromatographic methods were performed
using the FPLC System (Pharmacia Fine Chemicals, Piscataway, NJ). Anion exchange chro-
matography was done by loading samples onto the Mono Q HR 10/10 column equilibrated
in 20 mM Tris (pH 7.5) and eluting with a linear gradient of NaCl from 0 to 700 mM at
a flow rate of 4.00 ml/min. Chromatofocusing on the Mono P HR 5/20 column and gel
filtration on the Superose 12 HR 10/30 column are described in the figure legends. Elution
profiles were monitored by UV absorbance at 280 nm.
Miscellaneous Protein Manipulations.
￿
Protein preparations were concentrated in dialysis tub-
ing using Aquacide II (Calbiochem-Behring Corp., LaJolla, CA).
Results
Physicochemical Characterization ofSLEIFN-a.
￿
360 serum and plasma samples from
104 SLE patients were screened for the presence of IFN activity, and in agreement
with earlier reports (2, 3), 44 individuals (42%) exhibited significant IFN activity
(>8 IU/ml) on at least one occasion, while no normal serum or plasma (n = 7) ex-
hibited any IFN activity. The IFN activity from two SLE patients, DS and DT, was
found to conform to the previously reported acid-labile IFN-a. The IFNs from both
patients are reduced to <20% of original activity by anti-IFN-a antibodies, but are
unaffected by antibodies against IFN-(3 and IFN-y (Table I). This incomplete neu-
tralization has been observed by others (3, 4). Simultaneous incubation of the SLE
IFN with all threepanels of antibodies abrogates the IFN activity to the same degree
as with anti-IFN-a antibodies alone (data not shown), thus ruling out the presence
of trace amounts of IFN-0 or IFN-y in the plasma. In addition, the results in Table
II show that IFN activity from DS and DT is acid labile; standard IFN-a and IFN-(3
remain active after acid dialysis, while IFN-y, known to be acid labile, is inactivated.
The charge propertiesof SLE IFN-a from DS and DT were compared with those
of reference NK-2 IFN-ca by FPLC/Mono Qanion-exchange chromatography. Both
were found to bind avidly to the anion exchange column at pH 7 .5, requiring 250
to 300 mM NaCl to elute from the column (datanot shown). The similarity in charge
properties between SLE and standard IFN-a was further confirmed by chro-
matofocusing experiments (Fig. 1). SLE IFN was eluted from the Mono P column
by Polybufl'er around pH 5.1 (panel A), while the bulk of NK-2 IFN-a was eluted
within a pH range of 4.8 to 5.5 (panel B). All known subspecies of IFN-a have iso-
electric points between 5 .0 and 7 .0 (11).
1 Abbreviation used in this paper: FPLC, fast protein liquid chromatography.YEE ET AL.
TABLE I
Antibody Neutralization of Interferons
989
Representative results from multiple experiments (n = 3).
' Parentheses denote percent activity relative to control incubation with preimmune sera.
1 IFN-positive fractions were pooled after fractionation and concentrated before assay.
FPLC/Mono Qchromatography results in a 90-95% recovery and an approxi-
mately sixfold purification of SLE IFN activity (data not shown). Gel filtration of
Mono Q-enriched SLE IFN on the Superose 12 column revealed a single peak of
IFN activity, eluting in fractions correspondingto -19 kD, which is within the mo-
lecular mass range ofknown IFN-a subspecies (14) and coincident with the elution
of "'I-rIFN-ot2 (Fig. 2). Unpurified plasma SLE IFN-a also elutes in fractions cor-
responding to 19kD (datanot shown). This result and thehighrecovery yieldconfirm
that Mono Q-purified SLE IFN is representative ofthat in unfractionated plasma.
Further, antibody neutralization assays verify that Mono Q-purified IFN from DS
and DT is specifically inhibited by antibodies against IFN-CI (Table I).
SLE IFN-a is Acid Stable.
￿
More significantly, however, when Mono Q-purified
SLE IFN-a from DS and DT was dialyzed in acid, the IFN activity was completely
TABLE 11
Acid Stability of Interferons
Representative results from multiple experiments (n - 5).
' Samples were diluted in normal human plasma.
T Parentheses denote percent activity relative to control dialysis in PBS.
S IFN-positive fractions were pooled after fractionation and concentrated before assay.
Sample Preimmune
IFN titer
Anti-IFN-a
with antibody:
Anti-IFN-(3 Anti-IFN-y
IU/ml
NK-2 IFN-ce 256 <2 (<0.8%)' 256 (10057.) 256 (100%)
IFN-0 4,096 4,096 (100%) 384 (9.4%) 4,096 (1007 .)
IFN-y 2,048 2,048 (100%) 2,048 (100%) <2 (<O.I%)
DS-SLE (whole plasma) 384 64(16.7%) 384(100%) 384(100%)
DS-SLE (Post-Mono Q)T 192 32 (16.7%) 192 (100%) 192 (100%)
DS-SLE
(Post-Mono Q/Superose 12)1 64 8 (12.5%) 64(100%) 64(100%)
DT-SLE (whole plasma) 64 4(6.3%) 64 (100%) 64(100%)
DT-SLE (Post-Mono Q1 24 <2 (<8.3%) 24 (100%) 24 (100%)
Sample
IFN titer
PBS (pH 7.4)
with dialysis buffer of.
100 mM Glycine-HCI (pH 2.0)
IU/ml
NK-2 IFN-a' 512 512 (100%)T
IFN-S' 2,048 2,048 (100%)
IFN-y. 2,048 64(3.17 .)
DS-SLE (whole plasma) 128 16(12.5%)
DS-SLE (Post-Mono QS 192 192(100%)
DS-SLE (Post-Mono Q/Superose 12)S 256 256(100%)
DT-SLE (whole plasma) 128 4(3.1%)
DT-SLE (Post-Mono QS 48 48(100%)990
￿
LUPUS-ASSOCIATED INTERFERON a
i
I
I
I
I
I
i
I
I
m
a
0.4
0.3
0.2
0.15
0.0
Elution Volume (ml)
7.0
6.0
5.0 v
x
7.0
5.0
FICURE 1.
￿
FPLC/MonoPchromatofocusing of
(A)Mono Q-purified SLEIFNfrom DS plasma
and (B) NK-2 IFN-a. (A) Concentrated Mono
Q-purified IFN activity from DS was dialyzed
against 25 mM BisTris (Bis[2-hydroxyethyl]
imino-tris[hydroxymethyl] methane, pH 7.2) be-
fore beingfractionated into 1.00-ml fractionson
Mono P. Thecolumn wasequilibrated in 25 mM
Bis-Tris (pH 7.2), and sampleswere eluted with
Polybuffer 74 titrated to pH 4.0 (Pharmacia Fine
Chemicals) at aflow rate of0.75ml/min. (B)Ap-
proximately 3 x 103 IU of NK-2 IFN-a were
similarly chromatofocused. Antiviral activity of
fractions is illustrated by solid lines (-); absor-
bance ofeluate at 280 nm (A2sonm) is indicated
by evenly broken lines (- - -); pH gradients are
denotedby unevenly broken lines (- - - - - -).
unaffected (Table II), suggesting that the apparent acid lability of SLE IFN-a is
caused byotherfactor(s) in SLE plasma that areremoved during partial purification.
Acid-dependent IFN-inactivating Factor(s) in SLEPlasma.
￿
To test this hypothesis, the
effects ofSLEplasma on acid-stable NK-2 IFN-awere examined. NK-2 IFN-awas
diluted 1:10 (vol/vol) in plasma from either normal or SLE individuals to a final
concentration of512 1U/ml ofexogenous IFN activity and was then tested for acid
lability. Acid dialysis of NK-2 IFN-a diluted in plasma from DS and DT largely
Elution Volume (ml)
0
5
FIGURE 2.
￿
FPLC/Superose 12 gel filtration of
Mono Q-purified SLE IFN from DS plasma.
Mono Q-purified IFNactivity from DS wascon-
centrated, dialyzed in PBS, andthen fractionated
into 0.40-ml fractions at a flow rate of 0.50 ml/
min. Antiviral activity of fractions is illustrated
by solidlines(-); absorbance ofeluate at 280nm
(A28onm) is indicated by the evenly broken line
(- - -); molecular weight calibration is denoted
by the unevenly broken line (- - - - - -). The
Superose 12 column wascalibrated usingthefol-
lowing molecularmass standards: IgG(150 kD),
BSA (66.2 kD), OVA (42.7 kD), cytochrome c
(12.2 kD), and vitamin B12 (1,355 daltons). In
parallel experiments, 60 x 103 cpmof 1251-rIFN-
a2 were similarly fractionated; radioactivity of
individual fractions was quantitated with a
gamma counter (. - 0 - -).
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TABLE III
Acid-dependent Interferon-inactivating Activity
IFN titer
Without added
￿
With added'
NK-2 IFN-a
￿
NK-2 IFN-a
Representative results from multiple experiments (n = 3).
" The final concentration of added NK-2 IFN-a was 512 IU/ml.
i Acid dialysis resulted in >98% inactivation of IFN-y diluted in normal plasma.
S Parentheses denote percent activity relative to control dialysis in PBS.
N Separately pooled unbound and bound IFN-negative fractions from FPLC/Mono Q of plasma from DS
(see text).
inactivated the bulk of both exogenous and endogenous IFN activities (Table III).
Additional experiments reveal that 8 of 13 samples from other SLE patients also
exhibit similar acid-dependent IFN-inactivating activity and that the presence of
such activity is independent ofthe levels ofendogenous IFN (data not shown). No
normal plasma showed this property (Table III).
To further test the idea that the acid lability of SLE IFN-a is due to the effects
offactors not intrinsic tothe IFN, the IFN-negative fractions recovered during Mono
Q anion-exchange chromatography of plasma from DS were assayed for acid-
dependent IFN-inactivating activity. Fractions from the column flow-through and
from the salt eluate which lacked IFN activity were pooled separately and concen-
trated to original sample volume. The column flow-through, but not the salt eluate,
inactivated NK-2 IFN-a after acid dialysis (Table III), suggesting that factor(s) not
adsorbing to the Mono Qcolumn at pH 7.5 may account for the apparent acid la-
bility of SLE IFN-a.
Discussion
Four lines ofevidencehave been advanced inthis report to suggestthat SLE IFN-a
is physicochemically very similar to known IFN-a and that its acid lability is not
an intrinsicpropertyoftheSLE IFN-a, butrather the result ofother factor(s) present
in SLE plasma. First, with respect to antigenicity, size, and isoelectric point, SLE
IFN-a is indistinguishable from conventional IFN-a. Second, when SLE IFN-a is
partially purified by anion-exchange chromatography, it no longer exhibits acid la-
bility. Third, when exogenous acid-stableIFN-a is dilutedin SLE plasma orserum,
it as well as the endogenous IFN is inactivated after acid dialysis. And last, an acid-
dependent IFN-inactivating activity can be partially purified from SLE plasma by
anion-exchange chromatography.
These observations have important implications for the study ofthe IFN system
in SLE. Much effort has been expended to clone the large family ofhuman IFN-a
Sample Dialysis buffer: PBS (pH 7 .4) Glycine-HCI (pH 2)t
IU/ml
PBS (pH 7.4) Glycine-HCI (pH 2)
IU/mt
Normal plasma #1 <2 <2 512 512 (100%)S
Normal plasma #2 <2 <2 512 512 (100%)
DS-SLE (whole plasma) 256 48 (19%) 768 192 (25%)
DS-SLE (flow-through)ll <2 <2 512 128(25%)
DS-SLE (salt eluate)11 <2 <2 512 512 (100%)
DT-SLE (whole plasma) 128 4(3.1%) 512 24 (4.7%)992
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genesand pseudogenes, none ofwhich encode proteins that are acid labile (14). Since
it is now shown that SLE IFN-a is not intrinsically acid labile, it is quite possible
that one or more of the already described IFN-a may represent the IFN-a subspe-
cies observed in SLE. Thus, the necessary reagents for the study of the IFN system
in SLE may already be available for use. Indeed, various subspecies of IFN-a have
been shown to stimulate polyclonal B cell activation (15), to inhibit Ts cell function
(16), and to modulate expression of HLA class I antigens (17), all of which have
been implicated in the induction of autoimmunity. Alternatively, IFN-amaybe in-
volved in the efferent limb of pathology in SLE. Experimental and therapeutic ad-
ministration of IFN-a have been shownto causeclinical signs and symptoms of SLE-
like illness in animals and in humans (18).
The significance of acid-dependent IFN-inactivating factor(s) and whether this
activity is an integral component of theIFN system in SLE remain to be elucidated .
It has been reported that the acid stability of serum IFN-a in AIDS and AIDS-
related complex (ARC) decreases with progression of disease, perhaps secondary
to the increasing concentration of serum factors such as immunoglobulins, immune
complexes, andautoantibodies during the course ofillness (8). This speculation may
have relevance in SLE, since anti-IFN-a antibodies have been described in some
SLE patients (19). However, the nature of acid lability of IFN-a in AIDS/ARC also
has not been established, and it would be of interest to determine if findings with
acid-labile IFN-a in AIDS/ARC will be similar to those presented here for SLE.
Although a change in the acid stability of serum IFN-a in SLE over time has been
reported (4), no data on any relationship between acid stability and clinical disease
are available. In view ofthe increasingly recognized similarities between AIDSJARC
andSLE (7), such astudy mayshed lighton possible common pathogenetic or patho-
logical pathways in these disorders. Work to identify the acid-dependent IFN-
inactivating factor(s) is currently in progress.
Summary
The physicochemical properties of apparently acid-labile IFN-a from patients with
SLE have been studied. The antigenicity, apparent molecular size, and isoelectric
point of SLE IFN-ac are indistinguishable from those of conventional, previously
characterized, acid-stable subspecies of IFN-a. However, after partial purification
by anion-exchange chromatography, SLE IFN-a no longer exhibits acid lability, sug-
gestingthat other plasma factor(s) are responsible for the acid lability ofSLE IFN-a.
Addition of SLEplasma, butnot normal plasma, to conventional acid-stable IFN-a
renders the exogenous IFN-a acid labile. Preliminary results demonstrate that an
acid-dependent IFN-inactivating activity can be partiallypurified from SLE plasma
by anion-exchange chromatography.
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